Zobrazeno 1 - 10
of 192
pro vyhledávání: '"W. Ten Bokkel Huinink"'
Autor:
Jan H.M. Schellens, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Dick Pluim, Nadja E. van Egmond-Schoemaker, Wandena S. Siegel-Lakhai, David S. Boss
Supplementary Data from Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f36c9d0ed1e5d4002c17fae1ff6e120
https://doi.org/10.1158/1078-0432.22440754.v1
https://doi.org/10.1158/1078-0432.22440754.v1
Autor:
Jan H.M. Schellens, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Dick Pluim, Nadja E. van Egmond-Schoemaker, Wandena S. Siegel-Lakhai, David S. Boss
Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this interaction, the following phase I trial was designed to determine the safety and maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a184c2b5dbd6c1e1bdae501ee90c1d
https://doi.org/10.1158/1078-0432.c.6518044
https://doi.org/10.1158/1078-0432.c.6518044
Autor:
Jozef Sufliarsky, Wim W. ten Bokkel Huinink, Willem M. Smit, Stan B. Kaye, Hal W. Hirte, Stanislav Spanik, Amit M. Oza, A. Johri, Maria Wagnerova
Publikováno v:
Journal of Clinical Oncology. 27:3097-3103
Purpose To evaluate the safety, maximum tolerated dose (MTD), and pharmacokinetics of patupilone administered once every 3 weeks with proactive standardized diarrhea management in patients with resistant or refractory ovarian, fallopian, or peritonea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969ff5c0ae088c1d6d5cb088e2757e6c
https://doi.org/10.1200/jco.2008.20.4826
https://doi.org/10.1200/jco.2008.20.4826
Autor:
Martin J. Muller, Luc M.F. Moonen, Wim Meinhardt, Sanne B. Schagen, Willem Boogerd, Wim W. ten Bokkel Huinink, Frits S.A.M. van Dam
Publikováno v:
Acta Oncologica. 47:63-70
There is growing concern that some cytotoxic regimens for cancer affect cognitive functioning. This study examined the prevalence of cognitive complaints and deficits in testicular cancer (TC) patients treated with the worldwide standard BEP (bleomyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa164c0a273d704e747b33c9975f63b8
https://doi.org/10.1080/02841860701518058
https://doi.org/10.1080/02841860701518058
Autor:
Flora E. van Leeuwen, Ronald de Wit, Alexandra W. van den Belt-Dusebout, Berthe M.P. Aleman, Janine Nuver, Erik C. Schimmel, Jourik A. Gietema, P. Rodrigus, Wim W. ten Bokkel Huinink
Publikováno v:
Journal of Clinical Oncology, 24(3), 467-475. American Society of Clinical Oncology
Journal of Clinical Oncology, 24(3), 467-475. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 24(3), 467-475. AMER SOC CLINICAL ONCOLOGY
Purpose To evaluate the long-term risk of cardiovascular disease (CVD) in survivors of testicular cancer (TC). Patients and Methods We compared CVD incidence in 2,512 5-year survivors of TC, who were treated between 1965 and 1995, with general popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ae9a128d78cd9a495f243157d10c0b
https://doi.org/10.1200/jco.2005.02.7193
https://doi.org/10.1200/jco.2005.02.7193
Autor:
Isa E.L.M. Kuppens, Nadja E. Schoemaker, Patricia Lefebvre, Ger-Jan Sanderink, Wim W. ten Bokkel Huinink, Jan H.M. Schellens, Sylvie Assadourian, Jos H. Beijnen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:263-270
A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated dose (MTD), toxicity, preliminary antitumour response and pharmacokinetics. Irinotecan was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f117bdc4e7cca3f9498033525a97cad8
https://doi.org/10.1007/s00280-004-0874-2
https://doi.org/10.1007/s00280-004-0874-2
Autor:
Mirte M. Malingré, Ken Duchin, Olaf van Tellingen, Koopman Fj, M. Swart, Jan Lieverst, Jan H.M. Schellens, Hilde Rosing, Wim W. ten Bokkel Huinink, Jos H. Beijnen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:347-354
Purpose: To investigate dose escalation of bi-daily (b.i.d.) oral paclitaxel in combination with cyclosporin A in order to improve and prolong the systemic exposure to paclitaxel and to explore the maximum tolerated dose and dose limiting toxicity (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9aac7dc46d183777e7159aed0b47ab
https://doi.org/10.1007/s002800000226
https://doi.org/10.1007/s002800000226
Autor:
Koopman Fj, Margaret Schot, Hilde Rosing, Dick J. Richel, Jan H.M. Schellens, Wim W. ten Bokkel Huinink, Jos H. Beijnen, Mirte M. Malingré
Publikováno v:
Journal of Clinical Oncology. 19:1160-1166
PURPOSE: Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). In addition, metabolism of docetaxel by cytochrome P450 (CYP) 3A4 in gut and liver may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f807c970d11d16b4cab003d96cee6618
https://doi.org/10.1200/jco.2001.19.4.1160
https://doi.org/10.1200/jco.2001.19.4.1160
Autor:
Assad Chemaissani, Christian Manegold, Gunnar Wagenius, Kari Liippo, Wolfgang Dornoff, Willem W. ten Bokkel Huinink, Joachim von Pawel, N. v. Walree, Peter Drings, Karin Mattson, Sergio Ricci, Rolf A. Stahel, Christer Sederholm, Bengt Bergman, Piikko-Liisa Kellokumpu-Lehtinen
Publikováno v:
Lung Cancer. 26:85-94
This randomized study was designed to determine the response rates, survival and toxicities of single-agent gemcitabine (GEMZAR) and a combination of cisplatin/etoposide in chemonaive patients with non-resectable, locally advanced or metastatic non-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83efcb3eec62e84c1778f6e5aa90246e
https://doi.org/10.1016/s0169-5002(99)00067-7
https://doi.org/10.1016/s0169-5002(99)00067-7
Autor:
Jos H. Beijnen, Vinodh R. Nannan Panday, Wim W. ten Bokkel Huinink, Laurence J. C. van Warmerdam, M. T. Huizing, Jan H.M. Schellens
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 125:615-620
Purpose: Carboplatin doses are often determined by using modified Calvert formulas. It has been observed that the area under the concentration versus time curve (AUC) for free carboplatin is lower than expected when modified formulas are used for car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbe083f6b5b1eb531febe8c34be05e4
https://doi.org/10.1007/s004320050324
https://doi.org/10.1007/s004320050324